Syphilis — Staging, Testing, and Treatment

Key Points

• Syphilis is a systemic infection caused by Treponema pallidum with primary, secondary, latent, and tertiary manifestations; neurologic, ocular, and otic disease can occur at any stage.
• Stage the infection using symptoms, examination, prior test results, and timing of exposure.
• Treat primary, secondary, and early latent syphilis with benzathine penicillin G 2.4 million units IM once.
• Use Treponemal assay and other targeted evaluation to answer specific diagnostic or safety questions rather than ordering broad testing without a plan.
• Escalate urgently for neurologic deficit, meningitis, stroke syndrome, vision loss, uveitis, hearing loss, or cranial neuropathy.
• Other major warning findings include pregnancy with untreated syphilis or concern for congenital infection and treatment failure or fourfold titer increase suggesting reinfection or inadequate response.
• Medication and procedural choices should be matched to physiology, contraindications, renal/hepatic function, pregnancy status, and interaction risk when relevant.
• Repeat quantitative nontreponemal titers at guideline-recommended intervals and look for an appropriate decline.

Algorithm

1. Confirm that the presentation is consistent with Syphilis — Staging, Testing, and Treatment and identify immediately life-threatening alternatives or complications.
2. Obtain a focused history and examination that define severity, mechanism, relevant comorbidity, prior treatment, and baseline function.
3. Use targeted evaluation such as Treponemal assay, Quantitative RPR/VDRL, and other tests only when they can change management.
4. Classify the patient into a treatment pathway based on stability, disease/procedure subtype, organ function, and the presence or absence of escalation findings.
5. Begin the first-line intervention described for Syphilis — Staging, Testing, and Treatment, using the least complex safe regimen that directly treats the mechanism.
6. Reassess symptoms, vital signs, examination, laboratory or imaging response, and treatment toxicity after the first clinically meaningful interval.
7. Stop routine progression and escalate care for neurologic deficit, meningitis, stroke syndrome, vision loss, uveitis, hearing loss, or cranial neuropathy, pregnancy with untreated syphilis or concern for congenital infection, or treatment failure or fourfold titer increase suggesting reinfection or inadequate response.
8. At discharge or transition, document the final diagnosis, remaining uncertainty, medication/procedure plan, follow-up timing, prevention strategy, and explicit return precautions.

Clinical Synopsis & Reasoning

Syphilis is a systemic infection caused by Treponema pallidum with primary, secondary, latent, and tertiary manifestations; neurologic, ocular, and otic disease can occur at any stage. Diagnosis usually combines a treponemal test with a quantitative nontreponemal test such as RPR or VDRL. The quantitative titer is essential for treatment follow-up.

Stage the infection using symptoms, examination, prior test results, and timing of exposure. Primary syphilis often causes a painless chancre; secondary disease can cause diffuse rash including palms/soles, mucous patches, lymphadenopathy, and systemic symptoms. Latent infection has reactive serology without symptoms. Evaluate every patient for neurologic, ocular, and otic symptoms. Lumbar puncture is not routine for uncomplicated early syphilis but is indicated when neurologic findings suggest neurosyphilis. Test for HIV and other STIs.

The practical diagnostic task is to decide what must be established immediately, what can be clarified after stabilization, and which finding would change the working diagnosis. Useful evaluation elements include Treponemal assay, Quantitative RPR/VDRL, HIV/STI testing, CSF VDRL/cell count/protein. Each test should answer a defined question rather than be ordered reflexively. Serial examination is especially important when early results can be normal or when treatment itself changes the physiology being measured.

Infectious-disease management combines syndrome recognition, microbiology, source control, antimicrobial selection, and stewardship. The narrowest effective regimen should be used once the likely or confirmed pathogen is known. For Syphilis — Staging, Testing, and Treatment, the clinician should explicitly separate expected findings from escalation findings such as neurologic deficit, meningitis, stroke syndrome, vision loss, uveitis, hearing loss, or cranial neuropathy, pregnancy with untreated syphilis or concern for congenital infection, or treatment failure or fourfold titer increase suggesting reinfection or inadequate response.

Treatment Strategy & Disposition

Treat primary, secondary, and early latent syphilis with benzathine penicillin G 2.4 million units IM once. Late latent or unknown-duration syphilis is treated with 2.4 million units IM weekly for three doses. Neurosyphilis and ocular syphilis require aqueous crystalline penicillin G IV for 10-14 days under CDC-recommended regimens. Penicillin is the only proven therapy for syphilis during pregnancy; penicillin-allergic pregnant patients should be desensitized and treated with penicillin. Warn about the Jarisch-Herxheimer reaction—acute fever, myalgia, and symptom worsening after therapy—which is not penicillin allergy.

Repeat quantitative nontreponemal titers at guideline-recommended intervals and look for an appropriate decline. Sexual partners need evaluation and presumptive treatment according to exposure timing. Counsel to abstain from sexual contact until lesions are healed and partners have been managed.

Treatment should be reassessed after the first meaningful intervention rather than allowed to continue automatically. Relevant medications or therapeutic agents in this topic include Benzathine penicillin G 2.4 million units IM, Benzathine penicillin G weekly x3, Aqueous crystalline penicillin G IV, Doxycycline. Their usefulness depends on the indication, patient physiology, and contraindications shown in the sections below. If the response is poorer than expected, revisit the diagnosis, treatment delivery, adherence or access, procedure success when relevant, and the possibility of a complication.

Diagnostic specimens are most valuable when collected correctly and when the result can change therapy; broad testing without a clinical question can create false positives and unnecessary treatment. Follow-up must include treatment response, complications, transmission prevention when relevant, vaccination or prevention opportunities, and a plan for treatment failure.

Epidemiology / Risk Factors

• Syphilis — Staging, Testing, and Treatment is an important infectious-disease topic because timely treatment must be balanced with diagnostic accuracy and antimicrobial stewardship.
• Risk depends on host factors, anatomic site, severity, prior antimicrobial exposure, and the probability of resistant or complicated infection.
• Prevention, transmission control when relevant, and recognition of treatment failure are essential to reducing recurrence and complications.

Investigations

Syphilis Treatment by Stage

Pharmacology

Prognosis / Complications

• Outcome in Syphilis — Staging, Testing, and Treatment depends on baseline severity, underlying mechanism, comorbidity, speed of appropriate treatment, and whether major complications develop.
• Patients who respond as expected still need follow-up focused on recurrence prevention, treatment adverse effects, and restoration of function or physiologic stability.
• The appearance of neurologic deficit, meningitis, stroke syndrome, vision loss, uveitis, hearing loss, or cranial neuropathy or pregnancy with untreated syphilis or concern for congenital infection changes prognosis and should prompt a higher-acuity reassessment rather than routine outpatient progression.
• A durable plan is one that the patient can follow outside the clinical setting and that includes clear thresholds for returning to care.

Patient Education / Counseling

• Explain the diagnosis of Syphilis — Staging, Testing, and Treatment in plain language, including what is known, what remains uncertain, and what the immediate treatment is intended to accomplish.
• Review how the patient should take or use the recommended therapy and what common adverse effects or practical barriers to expect.
• Explain that worsening symptoms are not always a normal part of recovery and give specific return precautions for neurologic deficit, meningitis, stroke syndrome, vision loss, uveitis, hearing loss, or cranial neuropathy.
• Also seek prompt care for pregnancy with untreated syphilis or concern for congenital infection or treatment failure or fourfold titer increase suggesting reinfection or inadequate response.
• Discuss prevention or risk reduction relevant to the condition, including medication adherence, follow-up testing, rehabilitation, vaccination, sexual/partner management, or lifestyle factors as appropriate.
• Use teach-back at discharge so the patient or caregiver can state the treatment plan, follow-up timing, and reasons to return.

Notes

The main practical error in Syphilis — Staging, Testing, and Treatment is to reduce the topic to a memorized list without linking each action to a clinical purpose. A safer approach identifies the decision point, chooses the test or intervention that changes that decision, and then reassesses whether the patient is moving in the expected direction. Findings such as neurologic deficit, meningitis, stroke syndrome, vision loss, uveitis, hearing loss, or cranial neuropathy, pregnancy with untreated syphilis or concern for congenital infection, and treatment failure or fourfold titer increase suggesting reinfection or inadequate response should move the patient out of a routine pathway and into higher-acuity diagnostic or specialty assessment.

Documentation should make the reasoning reproducible. Record the baseline state, the key evidence supporting the diagnosis, major alternatives that were addressed, treatment actually delivered, response, and the follow-up responsibility. This is particularly important when multiple clinicians will share care or when a procedure, high-risk medication, evolving laboratory abnormality, or time-sensitive infection/vascular syndrome is involved. Once the patient is stable, the remaining work is prevention: address modifiable risk, treatment access, adherence, functional recovery, and the specific complication most likely to cause return to care.

References

1. CDC - STI Treatment Guidelines: Syphilis — Link
2. Infectious Diseases Society of America - Practice Guidelines — Link
3. CDC - Clinical Guidance — Link